Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate to Very Severe COPD is Beneficial
Phase 3 trial findings compared outcomes for COPD patients who had triple fixed-dose inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta₂ agonist with patients who received one of two dual-therapy combinations. The results were presented at the American Thoracic Society’s virtual clinical trial session.
A total of 8,509 patients were randomized on a 1:1:1:1 basis to receive twice daily:
Single-inhaler combinations of the inhaled corticosteroid (ICS) budesonide at one of two doses, the long-acting muscarinic antagonist (LAMA) glycopyrrolate, and the long-acting beta₂ agonist (LABA) formoterol.
Dual-therapy combination glycopyrrolate and formoterol.
Dual-therapy combination budesonide and formoterol.
The annual rate of moderate or severe COPD exacerbations was 1.08 and 1.07 for the triple combinations with 320 mcg and 180 mcg doses of budesonide, respectively, compared with 1.42 for glycopyrrolate-formoterol, and 1.24 for budesonide-formoterol.
Effect of Levothyroxine on LVEF in Patients With Subclinical Hypothyroidism & Acute MI
Locally Transplanted Adipose Stem Cells Reduce Anastomotic Leaks in Ischemic Colorectal Anastomoses in Rat Model
AIIMS e-ICU’s FAQcs On COVID-19
(Refresh the page or download this document incase the PDF doesn’t load properly)